HX GROUP(SH:600851)2021-04-27 16:00Financial Performance - Net profit attributable to shareholders increased by 80.56% to CNY 23,673,138.64 year-on-year, driven by increased investment income from Changxin Fund and Suzhong Pharmaceutical[11] - Operating revenue rose by 37.53% to CNY 254,199,834.90, primarily due to increased sales from Jiangxi Gannan Haixin Pharmaceutical Co., Ltd.[11] - Basic earnings per share increased by 79.82% to CNY 0.0196 compared to the previous year[11] - The weighted average return on equity improved by 0.2234 percentage points to 0.5635%[11] - Total operating revenue for Q1 2021 was $254.20 million, up from $184.83 million in Q1 2020, representing an increase of 37.4%[43] - Net profit for Q1 2021 was $23.42 million, significantly higher than $9.73 million in Q1 2020, marking an increase of 141.5%[45] - The total profit for the first quarter of 2021 was 18,755,740.79 CNY, compared to 12,977,921.37 CNY in the same period of 2020, representing an increase of approximately 44%[50] - The net profit for the first quarter of 2021 was 18,755,740.79 CNY, showing a significant improvement from a net loss in the previous year[50] Cash Flow - Net cash flow from operating activities reached CNY 75,419,564.92, a significant improvement from a negative CNY 16,268,112.59 in the same period last year[11] - Cash received from sales of goods and services increased by 42.19% to ¥325,237,950.47, compared to ¥228,736,899.93 in the previous year[21] - Cash flow from operating activities for the first quarter of 2021 was 75,419,564.92 CNY, a turnaround from a negative cash flow of -16,268,112.59 CNY in the first quarter of 2020[53] - The total cash and cash equivalents at the end of the period were $109.68 million, down from $173.47 million in the previous year[59] Assets and Liabilities - Total assets decreased by 5.74% to CNY 5,302,010,685.76 compared to the end of the previous year[11] - Current liabilities totaled ¥515,744,048.48, an increase from ¥497,377,650.81, driven by higher employee compensation and other payables[31] - Total liabilities increased from ¥1,245,567,071.88 to ¥1,145,786,469.55, a decrease of approximately 8.03%[33] - Total equity decreased from ¥4,379,498,999.59 to ¥4,156,224,216.21, a decline of about 5.09%[33] - The company's total equity attributable to shareholders decreased from ¥4,189,071,328.66 to ¥3,963,052,618.56, a decline of about 5.40%[33] Expenses - Sales expenses surged to ¥122,758,917.51, up 188.33% from ¥42,576,466.11, primarily due to increased product promotion costs[21] - Cash paid for taxes increased by 51.46% to ¥25,020,310.23, up from ¥16,519,622.26, mainly due to higher value-added tax payments[21] - Cash paid for other operating activities rose by 43.70% to ¥76,859,894.09, compared to ¥53,487,042.98, primarily due to increased product promotion expenses[21] - Research and development expenses decreased to $2.90 million in Q1 2021 from $3.69 million in Q1 2020, a reduction of 21.4%[43] Shareholder Information - The total number of shareholders at the end of the reporting period was 64,976, with the top ten shareholders holding a significant portion of shares[18] - The largest shareholder, Shenzhen Ningrui Investment Management Partnership, held 141,528,801 shares, accounting for 11.73% of total shares[18] Other Financial Information - The company reported a non-operating income of CNY 1,307,557.87, which includes various gains and losses[14] - The company has not disclosed any new product developments or market expansion strategies in this report[19]